No Data
No Data
Express News | Cellectar Biosciences Inc - Receives Nasdaq Notice on Minimum Bid Price Requirement
Express News | Cellectar Biosciences Inc Files for Offering of up to 19.2 Mln Shares by the Selling Stockholders - SEC Filing
Reported Earlier, Cellectar Highlights Path Toward Accelerated Approval For Iopofosine I 131 and Expands Radioconjugate Development
Cellectar Biosciences Reports 83.6% Overall Response Rate for Iopofosine I 131 in Phase 2 CLOVER-WaM Study, Plans for Advancement and Regulatory Approvals
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase During the JP Morgan Healthcare Conference
Express News | Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase During the JP Morgan Healthcare Conference
Unlock the Full List